Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)

臺大醫院-泌尿部;Sun, Y.Y.SunShi, H.H.ShiChen, C. -H.C. -H.ChenLee, J. L.J. L.LeeKang, T. W.T. W.KangPark, S. H.S. H.ParkWu, T. L.T. L.WuNg, Q. S.Q. S.NgKeam, B.B.KeamWong, S. C. A.S. C. A.WongTay, M. H.M. H.TayDing, Q.Q.DingLi, F.F.LiNg, D. C. E.D. C. E.NgLiu, X.X.LiuZhang, Z.Z.ZhangGuo, J.J.Guo陳忠信2017-09-272018-07-112017-09-272018-07-112015http://ntur.lib.ntu.edu.tw//handle/246246/283599[SDGs]SDG3Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)